ASB14780, an Orally Active Inhibitor of Group IVA Phospholipase A2, Is a Pharmacotherapeutic Candidate for Nonalcoholic Fatty Liver Disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

ASB14780, an Orally Active Inhibitor of Group IVA Phospholipase A2, Is a Pharmacotherapeutic Candidate for Nonalcoholic Fatty Liver Disease

Published:2015-12-23 Issue:3 Volume:356 Page:604-614
ISSN:1521-0103
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:Journal of Pharmacology and Experimental Therapeutics

Author:

Kanai S.,Ishihara K.,Kawashita E.,Tomoo T.,Nagahira K.,Hayashi Y.,Akiba S.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference55 articles.

1. Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis

2. Nonalcoholic Fatty Liver Disease

3. A temporal study on the histopathological, biochemical and molecular responses of CCl4-induced hepatotoxicity in Cyp2e1-null mice

4. A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Group IVA Phospholipase A<sub>2</sub> in Collagen-Producing Cells Promotes High-Fat Diet-Induced Infiltration of Inflammatory Cells into the Liver by Upregulating the Expression of MCP-1;Biological and Pharmaceutical Bulletin;2024-05-31

2. Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): Recent advances;Progress in Lipid Research;2023-07

3. Phospholipase A2 and hepatocellular carcinoma progression;Phospholipases in Physiology and Pathology;2023

4. Identification of potential inhibitor(s) against phospholipase A2 using a network pharmacology-based approach;Phospholipases in Physiology and Pathology;2023

5. Endothelial group IVA phospholipase A2 promotes hepatic fibrosis with sinusoidal capillarization in the early stage of non-alcoholic steatohepatitis in mice;Life Sciences;2022-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3